Lantern Pharma (LTRN) Operating Expenses (2019 - 2026)

Lantern Pharma (LTRN) has reported Operating Expenses for 8 consecutive years, with $3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 24.59% year-over-year to $3.5 million; the trailing twelve-month figure through Jun 2026 stood at $15.5 million (down 24.56% YoY), and the FY2025 full-year result was $18.0 million, down 19.08% from the prior year.
• Operating Expenses rose to $3.5 million in Q2 2026 per LTRN's latest filing, from $3.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $5.9 million in Q4 2024 and bottomed at $2.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $4.4 million across 5 years, with a median of $4.4 million in 2022.
• The widest YoY moves for Operating Expenses: up 77.28% in 2022, down 48.29% in 2022.
• Over 5 years, Operating Expenses stood at $3.8 million in 2022, then increased by 27.47% to $4.9 million in 2023, then climbed by 20.89% to $5.9 million in 2024, then decreased by 28.72% to $4.2 million in 2025, then slipped by 16.53% to $3.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $3.5 million, $3.4 million, and $4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.